Drugs / mRNA-1083
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05827926 | Apr 2023 → Dec 2024 | COVID-19, influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06864143 | Mar → Oct 2025 | Orthocoronavirinae infectious disease, influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06508320 | Jul 2024 → Sep 2025 | COVID-19, influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06694389 | Nov 2024 → Nov 2025 | COVID-19, influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06097273 | Oct 2023 → May 2024 | Orthocoronavirinae infectious disease, influenza | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1083 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06097273 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-based multicomponent vaccine (mRNA-1083), encoding seasonal influenza and SARS-CoV-2 antigens.” PMID 40102593 ↗ Mar 2025 |
| Route | Intramuscular | “single IM injection” NCT05827926 ↗ |